The last decade has seen a paradigm shift towards hybrid trials and DCTs. This transformation reached its peak during the COVID-19 pandemic with unprecedented challenges faced by the clinical community, including interrupted trials and potential impact on the lives of millions of patients.
The choice between a PD or BYOD in clinical trials is based on the protocol data capture needs, sponsor preference, patient needs, and risk mitigation. Ethics committee approvals can also influence the decision. However, when it comes to the quality of data – a core requirement in a clinical trial – evidence is growing for there being no difference.
The challenges that the sponsor must assess while deciding whether to use PDs or BYOD are diverse.
We share what we have learnt, along with our clients, about the benefits and risks of using PD or BYOD for sponsors, sites, and patients.
Our whitepaper sets out several findings including
Most participants have their own smartphone, and use it with confidence
Our results also debunk the myth of older adults not being comfortable with technology and with sharing their data.
BYOD has the edge over Provisioned Devices
We present a summary of three ongoing global clinical trials where our Atom5™ platform has been used to support our view.
The use of smartphones in drug development continues to grow
Our evidence over the past nine years has shown that the rapid adoption of smartphones supports the use of a BYOD strategy in DCTs and hybrid clinical trials.